ANAB
HealthcareAnaptysBio, Inc.
$43.20
$-1.75 (-3.89%)
Jan 5, 2026
Price History (1Y)
Analysis
AnaptysBio, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $1.21 billion and annual revenue of $169.47 million. The company has a workforce of 136 employees. The company's financial health shows significant losses, with net income totaling -$84,630,000 and EBITDA at -$28,102,000 over the trailing twelve months. However, its gross margin is at 9.7%, while operating and profit margins are 45.5% and -49.9%, respectively. AnaptysBio's cash reserves stand at $248.96 million, but it also has debt of $346.45 million. AnaptysBio's valuation metrics show a forward P/E ratio of -10.67 and price to book ratio of -40.49. The company's revenue growth over the past year was 154.3%, although earnings growth is not available. Its current ratio is at 8.68, indicating sufficient liquidity.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About AnaptysBio, Inc.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $1.21B
- P/E Ratio
- N/A
- 52-Week High
- $52.47
- 52-Week Low
- $12.21
- Avg Volume
- 508.98K
- Beta
- 0.32
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 136